Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
Takeda Pharmaceutical said on July 19 that a subcutaneous formulation of vedolizumab met the primary endpoint in a PIII study investigating its efficacy and safety as a maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC).…
To read the full story
Related Article
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
BUSINESS
- Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
September 10, 2026
- 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
- Elix, Axcelead DDP Forge Pact on Novel Protein Degraders
September 10, 2026
- CMIC Scraps Application Forms, Brings AI Avatars into New Grad Hiring
September 10, 2026
- Teijin, Shinshu University Link Arms on CAR-T Manufacturing
September 10, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…